Press & media

Pressreleases

Spermosens recruits first couple for clinical study on next-generation male fertility diagnostic product

04-10-2024

Spermosens AB (“Spermosens” or the “Company”) is pleased to announce a significant milestone in its clinical study of the next-generation fertility diagnostic product. The first couple has now been recruited for the study, which is designed to assess the diagnostic value of JUNO-Checked in male infertility. The clinical study, currently underway at the Reproductive Medicine…

Read more at Cision

Kallelse till extra bolagsstämma i Spermosens AB (publ) för beslut om emission

03-10-2024

Aktieägarna i Spermosens AB (publ), org.nr 559179–0380, (”Spermosens” eller ”Bolaget”) kallas härmed till extra bolagsstämma den 4 november 2024 kl. 16:00 på The Spark, Medicon Village, Scheeletorget 1, Lund. På den extra bolagsstämman ska ägarna ta ställning till förslag om minskning av aktiekapitalet, emission med företrädesrätt för aktieägare för att ta in ytterligare kapital, samt…

Read more at Cision

Spermosens carries out a rights issue of units of approximately SEK 22.7 million

03-10-2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, the…

Read more at Cision

Spermosens next-generation male fertility diagnostic product ready for clinical study

25-09-2024

Spermosens AB ("Spermosens" or the "Company") is pleased to announce the development of the next-generation of its JUNO-Checked device, a groundbreaking product designed to assess male fertility potential. Developed in collaboration with Flex Medical Solutions (FMS), this next-generation JUNO-Checked device will play a pivotal role in the upcoming clinical study, which has recently received ethical…

Read more at Cision

Spermosens passes an important milestone receiving approval for significant clinical study.

26-08-2024

Spermosens AB announces that the Swedish Ethical Review Authority has given approval for the company’s application to start a clinical study at Reproductive Medicine Center (RMC) in Malmö with JUNO-Checked to evaluate sperm quality for couples undergoing fertility treatment. This means that the company now takes the next step in validating diagnostic use of JUNO-Checked.

Read more at Cision

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2024

20-08-2024

The revised strategy positions Spermosens optimally to unlock the full potential of its groundbreaking product. Spermosens AB's interim report for the period January - June 2024, is now available on the Company's website and attached to this press release.

Read more at Cision

Articles

Presentations

BioStock Investor Pitch: Spermosens
April 11, 2024 Vd Ulrik Nilsson presenterar bolaget, deras patentskyddade teknologi och strategierna för framtiden för Biostock studio.
Company Presentation at Medicon Village
Mar 28, 2023 Spermosens CEO Ulrik Nilsson present the company at Medicon Village
Company Presentation
Jan 18, 2023 Spermosens CEO Ulrik Nilsson present the company at Finwire
Investor Pitch: Spermosens
Jan 17, 2023 Watch BioStock presentation
Spermosens Showcase Presentation
Nov 14, 2022 Spermosens CEO Ulrik Nilsson, recorded at the 2022 Investival Showcase in London.
Stora Aktiedagen in Stockholm
Nov 30, 2021 For those of you who missed the presentation at Stora Aktiedagen, Aktiesparararna, or if you want to watch it again, you find the recorded broadcast here.
Company presentation and Q&A
Jun 9, 2021 Presentation and Q&A session with Aktiespararna after the IPO 2021.
Company presentation and Q&A
Mar 31, 2021 Presentation and Q&A session with Aktiespararna during the IPO 2021.
Investor Presentation
Mar 25, 2021 Spermosens CEO John Lempert present the company in the Biostock Studio during the IPO 2021.

Interviews

Lösningen på ofrivillig barnlöshet? (SWE)
April 8th, 2024 Watch BioStock presentation
SPERMOSENS OM EMISSIONEN (SWE)
Jan 17, 2023 Watch BioStock presentation
HETA STOLEN: INTERVJU MED SPERMOSENS (SWE)
Jan 17, 2023 Read article at Impala Nordic
Meet the company
Sep 13, 2021 Spermosens CEO John Lempert is interviewed by Mikael Bak at Dansk Aktionærforening in a talk about how the company has developed since the IPO in May.
QA Interview with our CEO
Aug 19, 2021 Spermosens CEO John Lempert is interviewed in Aktier – Live Sessions, the biggest Facebook group in the Nordics covering the stock market. This was recorded on Aug 19th, the day we published our interim report Q2 2021. The topics are connected to the progress made since the IPO.
Interview with our CEO
Apr 8, 2021 Spermosens CEO John Lempert is interviewed by Nordnet during the IPO 2021.
Company Interview
Mar 30, 2021 Spermosens CEO John Lempert is interviewed in the Biostock Studio during the IPO 2021.
Podcast with our CEO
Mar 27, 2021 Spermosens CEO John Lempert is interviewed by Ophelia Invest during the IPO 2021.

Spermosens Logotype

Logotype PNG
RGB, Black, White
Logotype EPS
RGB, Black, White
Logotype EPS
PMS

Photos

The Technology

Learn more